Foghorn Therapeutics (FHTX) Stock Forecast & Price Target

Foghorn Therapeutics is attractive fundamentally because its selective EP300 and CBP degrader strategy may preserve the efficacy seen with dual EP300/CBP inhibition while avoiding the platelet toxicity that has constrained competitors such as inobrodib. The company’s preclinical EP300 data show complete responses and tumor regression in pomalidomide-resistant models with a more favorable safety profile, while the planned IND toward the end of 2027 and potential initial data in 1H29 create a clear path to value-inflection in heme malignancies. Although FHD-909 was discontinued after Phase 1 dose escalation failed to deliver sufficient efficacy, the $168M of cash at Q2:26 and expected runway into H2:29 after a ~40% workforce reduction support continued development of the wholly owned pipeline.

Foghorn Therapeutics is facing a weakened fundamental outlook because FHD-909, its only clinical-stage asset, showed favorable safety and target engagement but failed to deliver the efficacy needed to justify Phase 1 expansion, effectively undermining the company’s lead synthetic-lethality thesis. The loss of the Lilly collaboration and discontinuation of the SMARCA2 degrader program remove a major source of external validation and partnered value, while the remaining pipeline is now fully preclinical, with the oral I&I and EP300 assets not expected to be IND-ready until late '27 and clinical data still unproven. Although a ~40% workforce reduction extends runway into H2:29, that only buys time for earlier-stage programs that still require additional capital or a partner, making the risk-reward profile more defensive.